Skip to main content Back to Top


Norepinephrine Bitartrate Injection

Products Affected - Description

    • Levophed injection, Pfizer, 1 mg/mL, 4 mL ampule, 10 count, NDC 00409-1143-04 - discontinued
    • Norepinephrine injection, Hikma, 1 mg/mL, 4 mL vial, 10 count, NDC 00143-9318-10

Reason for the Shortage

    • Baxter has norepinephrine injection available.
    • Hikma did not provide a reason for the shortage.
    • Mylan Institutional has norepinephrine injection available.
    • Pfizer has Levophed vials available. The ampules were discontinued in December 2019.
    • Teva has norepinephrine injection available.

Available Products

    • Levophed injection, Pfizer, 1 mg/mL, 4 mL vial, 10 count, NDC 00409-3375-04
    • Norepinephrine injection, Baxter, 1 mg/mL, 4 mL ampule, 10 count, NDC 36000-0162-10
    • Norepinephrine injection, Mylan Institutional, 1 mg/mL, 4 mL vial, 10 count, NDC 67457-0852-04
    • Norepinephrine injection, Teva, 1 mg/mL, 4 mL vial, 10 count, NDC 00703-1153-03

Estimated Resupply Dates

    • Hikma has norepinephrine 1 mg/mL 4 mL vials available with short expiration dating (June 2021).


Updated November 24, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. Created February 22, 2017 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.


Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.